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Metaphyseal dysplasia with maxillary hypoplasia and brachydactyly (MDMHB) is an autosomal-dominant bone dysplasia characterized
by metaphyseal flaring of long bones, enlargement of the medial halves of the clavicles, maxillary hypoplasia, variable brachydactyly,
and dystrophic teeth. We performed genome-wide SNP genotyping in five affected and four unaffected members of an extended family
with MDMHB. Analysis for copy-number variations revealed that a 105 kb duplication within RUNX2 segregated with the MDMHB
phenotype in a region with maximum linkage. Real-time PCR for copy-number variation in genomic DNA in eight samples, as well
as sequence analysis of fibroblast cDNA from one subject with MDMHB confirmed that affected family members were heterozygous
for the presence of an intragenic duplication encompassing exons 3 to 5 of RUNX2. These three exons code for the Q/A domain and
the functionally essential DNA-binding runt domain of RUNX2. Transfection studies with murine Runx2 cDNA showed that cellular
levels of mutated RUNX2 were markedly higher than those of wild-type RUNX2, suggesting that the RUNX2 duplication found in
individuals with MDMHB leads to a gain of function. Until now, only loss-of-function mutations have been detected in RUNX2; the
present report associates an apparent gain-of-function alteration of RUNX2 function with a distinct rare disease.Metaphyseal dysplasia with maxillary hypoplasia and
brachydactyly (MDMHB [MIM 156510]) is an autosomal-
dominant bone dysplasia first described by Halal et al. in
1982 in a French Canadian family from the Gaspe´sie
region in Quebec.1 Affected family members hadmetaphy-
seal flare and thin diaphyseal cortices of long bones,
bilateral shortness of middle phalanxes or metacarpals,
and maxillary hypoplasia. Other skeletal anomalies
included mild short stature, enlargement of the medial
halves of the clavicles, wide ischial and pubic bones,
mild thickening of frontal and parietal skull bones, platy-
spondyly, and a general radiographic impression of osteo-
porosis, even though bone density measurements were
not reported. Teeth were yellowish and dystrophic, leading
to total dental extraction before the end of the second
decade in the majority of affected individuals. No extra-
skeletal abnormalities were noted. It appears that no
further MDMHB cases have been reported since this initial
description.
We have identified six individuals from a kindred whose
clinical and radiographic phenotype closely resembles that
of the subjects described by Halal et al.1 and who also
originate from the Gaspe´sie region in Quebec (Figure 1;
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IV-1, IV-2, and IV-6) showed thin cortices and a low
amount of trabecular bone (Figure 1K). Mineral apposition
rate, a marker of bone formation, was low, suggesting
a defect in osteoblast function, whereas osteoclast surface,
a marker of bone resorption, was normal (Figure 1L).
Biochemical parameters of bone and mineral metabolism
were mostly within normal limits (Table S3). Lumbar spine
bone mineral density was low (z score < 2) for three
subjects but was within normal limits for the others.
However, peripheral quantitative computed tomography
of the radius showed that cortices were very thin at both
the metaphysis and the diaphysis (Table S3).
To search for the disease-causing mutation in this
family, we obtained DNA from five affected and four
unaffected family members (Figure 1A). With approval
from the Institutional Review Board of McGill University,
we obtained informed consent; assent was obtained
from participants aged less than 18 years. We performed
whole-genome SNP genotyping in all nine individuals
with the Human Omni2.5-Quad chip (Illumina, San
Diego, CA). MERLIN software (version 1.1.2) was used
for parametric linkage analysis after pruning for linkage
disequilibrium.2 The maximum achievable LOD score ofa; 2Department of Human Genetics, McGill University, Montre´al, QC H3A
pital of WGKK and AUVA Trauma Center Meidling, 1st Med. Department,
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Figure 1. Clinical Information on a Family with MDMHB
(A) Pedigree. Individuals who contributed DNA for SNP genotyping are marked with an asterisk.
(B) Dental phenotype of subject IV-5 at 20 years of age, showing dysplastic and yellowish teeth.
(C–J) Radiographs of subject IV-5 at the age of 20 years, showing a thick cranial vault (C) as well as undermodeled metaphyses and
thin cortices at hand and wrist (D), humerus (E), forearm (F), and lower extremities (G); enlarged medial portions of the clavicles
(H, dashed lines surround the clavicles, the arrows show the precise location of the bone contour); widened symphysial arches of the
ischial (arrows) and pubic bones (I); and irregular shape and compression of vertebrae (J).
(K) Transiliac bone biopsy specimen from a control subject (top) and from subject IV-6 (bottom), both aged 17 years, showing enlarged
bone size, thin cortices, and a low amount of trabecular bone in the sample from the affected individual.
(L) Histomorphometric results for samples from subjects IV-1, IV-2, and IV-6 and for age-matched controls (n¼ 12; fromGlorieux et al.11).
Mean (error bars: SE) results for cortical width (Ct.Wi), trabecular bone volume per tissue volume (BV/TV), mineral apposition rate
(MAR), and osteoclast-covered surface per bone surface (Oc.S/BS) are shown.2.1 was obtained for regions on chromosomes 6, 11, and
15 (Table S4). Genomic DNA from subjects IV-1 and IV-5
was captured with the Agilent SureSelect 50 MbThe Americoligonuclotide library (Agilent Technologies Inc., Santa
Clara, CA) and was sequenced with 100 paired-end
reads on Illumina HiSeq2000. By using a bioinformaticsan Journal of Human Genetics 92, 252–258, February 7, 2013 253
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Figure 2. Duplication in RUNX2
(A) The genomic organization of the
RUNX2 locus on chromosome 6. The
RUNX2 gene has nine exons. The first
two exons of SUPTH3, which is transcribed
in the opposite direction (arrow), overlap
with intron 2 of RUNX2. The locations
analyzed by qPCR for copy number state
are indicated by circled numbers.
(B) The qPCR analysis shows copy number
state three for affected individuals III-2,
III-3, IV-1, and IV-5 at locations 2
(Hs01529684_cn; location 45,332,959)
and 3 (Hs04907414_cn; location 45,412,
249), but copy number state two at
locations 1 (Hs04922096_cn; location
45,292,671) and 4 (Hs06792104_cn; loca-
tion 45,420,087). Unaffected individuals
III-1, III-4, IV-3, and IV-4 have a copy
number state two at all locations.
(C) Protein structure of wild-type RUNX2
(top) and RUNX2 with duplica-
tion of exons 3 to 5. The RUNX2 domains
are Q/A (poly Q/A repeat), Runt (runt
domain), NLS (nuclear localization se-
quence), and PST (proline/serine/threo-
nine-rich domain). The border positions
of the corresponding exons are shown
by the numbers and dotted vertical lines.
The position of the primers used for PCR
and sequencing of fibroblast cDNA of
subject IV-6 is shown by arrows labeled
F and R. Only cDNA carrying the duplica-
tion will result in a PCR product. No PCR
amplification occurs when primers anneal
to the unmutated cDNA (locations F0 and
R0, in gray).pipeline as previously described,3 we found that the 2
subjects shared 17 previously undescribed variants, none
of which were located within any of the linkage regions.
The SNP array data were analyzed for copy-number
variations (CNV) with PennCNV, IPN, CNVpartition, and
QuantiSNP algorithms. These CNV analyses showed that
all affected individuals of the pedigree had a 105 kb
duplication within the linked region on chromosome
6 (chromosomal location 6p12.3; physical position 6:
45,308,920–45,413,885; hg19) whereas this duplication
was absent in all unaffected family members (Figure S1).
Smaller duplications affecting intronic areas within this
region have been reported in CNV databases.
The duplicated sequence contains exons 3 to 5 of RUNX2
(MIM600211,RefSeq accessionnumberNM_001024630.3)
and exons 1 and 2 of SUPT3H (MIM 602947) (Figure 2A).
The function of SUPT3H (suppressor of Ty 3 homolog)
is unknown. If the duplicated exons of SUPT3H are
transcribed, they would lead to a frameshift and probably254 The American Journal of Human Genetics 92, 252–258, February 7, 2013result in nonsense-mediated decay.
We therefore judged it unlikely
that the effect of the duplication
on SUPT3H is involved in the patho-
genesis of MDMHB and did notinvestigate this gene further. In contrast, RUNX2 codes
for a transcription factor that is essential for bone forma-
tion.4,5 RUNX2 haploinsufficiency leads to cleidocranial
dysplasia (CCD [MIM 119600]).6,7 A duplication of
exons 3 to 5 is predicted to lead to an in-frame addition
to the RUNX2 sequence. We therefore performed further
investigations on RUNX2.
The duplication was confirmed by real-time PCR in
genomic DNA from four affected and four unaffected
family members (Figure 2B). All affected individuals had
three copies for the two locations within the sequence
affected by the duplication, but two copies at locations
telomeric and centromeric of this region.Unaffected family
members had two copies for all four locations. This
confirmed the presence of a duplication that stretches
from intron2 to intron5ofRUNX2 and thus includes exons
3 to 5 of RUNX2. These three exons code for the Q/A
domain and the runt domain of RUNX2 (Figure 2C). The
Q/A domain consists of a stretch of 23 glutamine residues
A B
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p.Arg236Asn
Figure 3. Functional Characterization
of the Intragenic RUNX2 Duplication
(A) Immunoblot analysis of mouse RUNX2
proteins (mRUNX2) overexpressed in
HEK293 cells. Cells were transfected with
equal amounts of expression plasmids
encoding green fluorescent protein (GFP),
wild-type mouse RUNX2 (wt mRUNX2),
or mutant mouse RUNX2 (mut mRUNX2)
carrying a duplication of exons 3 to 5. At
the indicated time points after transfec-
tion, total cellular extracts were prepared
and analyzed by immunoblotting.
The asterisk points to an undetermined
minor immunoreactive protein that
appears only in lanes containing mutant
mRUNX2. The blot was rehybridized for
actin as a loading control. RUNX2 protein
levels are much higher for the mutated
than for the wild-type protein at all three
time points.
(B) Relative activity of the mouse 1.1 kb
osteocalcin promoter-luciferase reporter
construct 42 hr after cotransfection with
300 ng of plasmids encoding the wild-
type mouse RUNX2, the mutant mouse
RUNX2, or the wild-type mouse RUNX2 harboring a missense mutation (p.Arg236Asn, corresponding to a p.Arg229Asn change in
human RUNX2). Data represent means 5 SD from three independent experiments and are expressed as fold induction relative to
the GFP control. The duplication in RUNX2 leads to higher transactivation activity, whereas the p.Arg236Asn mutation is associated
with lower transactivation activity.
(C) Backscattered electron image of iliac bone sample from subject IV-1.
(D) Results of bone mineralization density distribution analysis in trabecular bone from subjects IV-1, IV-2, and IV-6, compared to
age-matched reference data in cancellous bone (Cn-Young).22 In all three samples the distribution curve is shifted toward higher miner-
alization density compared to control values.followed by 17 alanine residues. The runt domain is the
functionally essential DNA binding domain of RUNX2.8
The duplication of exons 3 to 5 was confirmed with
cDNA derived from a fibroblast line from subject IV-6.
PCR amplification and sequencing by a forward primer
in exon 4 and a reverse primer in exon 3 in the subject’s
cDNA resulted in a PCR product of the predicted length
and sequence, confirming that exon 5 was followed by
exon 3 and thus proving the forward orientation of the
duplication (Figure 2C). This duplication also results in
a c.686_687delinsAT (p.Arg229Asn) (NM_001024630.3)
change at the breakpoint between exon 5 and exon 3.
On the protein level, the duplication of exons 3 to 5 of
RUNX2 thus leads to a p.[Pro21_Arg229dup; Arg229Asn]
change. Residue 229 of RUNX2 is an evolutionary
conserved amino acid (Figure S2).
The functional consequences of the duplication in
exons 3 to 5 of RUNX2 were assessed by introducing a
similar duplication in murine Runx2 cDNA. The construct
led to the duplication of amino acids 25 to 232 of murine
RUNX2 (corresponding to residues 25 to 225 in human
RUNX2) and included the Q/A and runt domains, with
the exception of the last four amino acids of the runt
domain (Figure S2). Equal amounts of expression plasmids
containing mutated and wild-type Runx2 cDNA were
transfected into HEK293 cells. The resulting intracellular
RUNX2 proteins migrated at their predicted molecular
masses of 57 kDa and 80 kDa, respectively (Figure 3A).The AmericProtein levels were markedly higher for the mutated
RUNX2 than for wild-type RUNX2. In addition, we com-
pared the transactivation activity of the mutant to that
of the wild-type RUNX2, using a reporter construct based
on the mouse osteocalcin promoter, which has been well
characterized as an osteoblast-specific target of RUNX2.8
Cotransfection of equal amounts of these constructs in
HEK293 cells demonstrated increased transactivation
activity for the mutated RUNX2 (Figure 3B). A separate
analysis of the functional effect of the isolated Arg to Asn
change at the breakpoint residue 229 showed that this
sequence change led to decreased transactivation activity
(Figure 3B). Overall, these transfection experiments sug-
gested that the duplication of exons 3 to 5 leads to some
loss of transactivation activity of the RUNX2 protein as
a result of the amino acid change at residue 229, but
a marked increase in intracellular RUNX2 protein levels,
with the composite effect of a gain in function.
Mice overexpressing Runx2 in osteoblasts have an ab-
normally low number of osteocytes in cortical bone.9,10
We therefore determined cortical osteocyte density in the
iliac bone samples from subjects IV-1, IV-2, and IV-6 and
in three age-matched control samples that were taken
from our reference collection.11 This revealed that
osteocyte density (the number of osteocytes relative to
the cortical bone area of the section) was 32% lower in
the samples from affected individuals than in controls
(mean 5 SE: 186 5 13 mm2 versus 272 5 4 mm2).an Journal of Human Genetics 92, 252–258, February 7, 2013 255
Runx2 transgenic mice have a lower-than-normal average
material density of trabecular bone.10 Therefore, material
bone density was also determined in the iliac bone samples
from subjects IV-1, IV-2, and IV-6, but in contrast to the
mouse studies we found that material density was slightly
increased compared to controls (Figure 3C).
In this report we present a kindred in which several
members presented with the MDMHB phenotype. Even
though the family link to the MDMHB kindred described
by Halal et al.1 could not be ascertained, the family pre-
sented here had strikingly similar features and originated
from the same geographic area. The main phenotypic
difference between the two families is that Halal et al.1
had reported brachydactyly, whereas acral abnormalities
were not observed in the individuals presented here.
However, brachydactyly was an inconsistent feature in
the family described by Halal et al.1 Therefore, we consider
it very likely that the family described by Halal et al.1
and the individuals presented here have in fact the same
disorder, MDMHB, and may in fact be individuals from
the same extended family.
RUNX2 is the master regulator of both osteoblast and
terminal chondrocyte differentiation and is essential for
in vivo bone formation and mineralization.4,12 A large
number of bone-related genes are regulated by RUNX2,
which binds to DNA and heterodimerizes with the tran-
scriptional coactivator core binding factor b.13 Both of
these functions are mediated by the runt domain that is
duplicated in individuals with MDMHB.14
Until now, CCD has been the only disorder associated
with RUNX2 mutations. All of the more than 170 RUNX2
mutations reported until now are believed to result in
loss of RUNX2 function and lead to CCD.6–8,15 MDMHB
affects similar skeletal sites as CCD, but in some ways
represents the mirror image of CCD. Clavicles are enlarged
in MDMHB but are hypoplastic or absent in CCD. In
MDMHB, the cranial vault is thickened whereas there is a
lack of skull mineralization in CCD. Persons with MDMHB
present with dystrophic teeth, whereas CCD is associated
with supernumerary teeth. The MDMHB phenotype is
also different from that caused by duplications of the
entire RUNX2 locus, which are associated with suscepti-
bility to premature cranial suture fusion.16,17
The clinical findings of MDMHB and the results of our
mechanistic studies are in accordance with the notion
that the duplication of exons 3 to 5 leads to a gain of func-
tion in RUNX2. This gain of function may result from
increased cellular levels of mutated RUNX2 protein, as sug-
gested by our transfection experiments. The mechanism
leading to this increase in levels of mutated RUNX2
protein was not investigated in this study, but it is known
that RUNX2 levels are regulated by complex posttrans-
lational modifications.18 One or several of these posttrans-
lational modification pathways may be affected by the
duplication. The situation is made even more complicated
by the fact that the duplication of exons 3 to 5 in RUNX2
not only leads to the addition of 209 amino acids to the256 The American Journal of Human Genetics 92, 252–258, Februaryprotein but also introduces an amino acid change at the
breakpoint residue 229, which by itself seems to lead to
a decrease in transactivation activity of RUNX2. Possibly,
the marked increase in the amount of mutated protein
overrides this decrease in function.
RUNX2 is an important regulator of osteoblast function,
so it may be surprising that the in vivo consequence
of this putative gain-of-function mutation was decreased
osteoblast activity, as shown by the lowmineral apposition
rate in bone samples of subjects with MDMHB. A similar
discrepancy between in vitro and in vivo effects was found
in Runx2-overexpressing mice.19 A possible explanation
is that RUNX2 must be suppressed during osteoblast
differentiation for immature osteoblasts to become fully
mature.9,10,20 A gain of RUNX2 function may therefore
interfere with osteoblast maturation, which is consistent
with our observation that in bone tissue of individuals
with MDMHB there are fewer-than-normal osteocytes, the
terminal stage of osteoblast maturation. Correspondingly,
mice overexpressing Runx2 in osteoblasts have a severe
deficit in bone formation, leading to thin long-bone
cortices, low bone mass, and low osteocyte density.9,10
Similarly, overexpression of Runx2 in odontoblasts inter-
feres with the maturation of these cells and leads to disor-
dered tooth structure.21 These skeletal and dental features
of Runx2 overexpression in mice were also present in
individuals with MDMHB. However, it appears that bones
arising through intramembranous bone formation (skull,
clavicle) do not follow the same pattern; indeed, the
radiographic appearance of clavicles and skull suggests
that the amount of bone is increased at these locations.
The effect of Runx2 overexpression on bone resorption
is somewhat inconsistent between mouse models; both
normal and markedly elevated bone resorption have
been reported.9,10 In subjects with MDMHB, there was
no indication of increased bone resorption and bone
turnover seemed to be somewhat low. This is consistent
with the finding that material bone density was slightly
elevated in the bone samples from these individuals. Lower
bone turnover means that the average time since bone
deposition at a given skeletal location is higher, allowing
more time to complete bone matrix mineralization.
In summary, this report shows that MDMHD is caused
by a duplication in RUNX2 that may lead to a gain-of-
function and a bone formation defect, thus enlarging
the phenotypic spectrum associated with dysregulation
of RUNX2 function.Supplemental Data
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